Your browser doesn't support javascript.
loading
Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast.
da Silva, Edaise M; Beca, Francisco; Sebastiao, Ana Paula Martins; Murray, Melissa P; Silveira, Catarina; Da Cruz Paula, Arnaud; Pareja, Fresia; Wen, Hannah Y; D'Alfonso, Timothy M; Edelweiss, Marcia; Weigelt, Britta; Brogi, Edi; Reis-Filho, Jorge S; Zhang, Hong.
Afiliação
  • da Silva EM; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Beca F; Pathology, Stanford University School of Medicine, Stanford, California, USA.
  • Sebastiao APM; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Murray MP; Department of Medical Pathology, Universidade Federal do Parana Setor de Ciencias da Saude, Curitiba, Brazil.
  • Silveira C; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Da Cruz Paula A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Pareja F; GenoMed SA, Institute of Molecular Medicine, University of Lisbon, Lisboa, Portugal.
  • Wen HY; Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • D'Alfonso TM; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Edelweiss M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Weigelt B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Brogi E; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zhang H; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J Clin Pathol ; 75(2): 133-136, 2022 Feb.
Article em En | MEDLINE | ID: mdl-33376197
AIMS: Here we explore the presence of mediator complex subunit 12 (MED12) exon 2 and telomerase reverse transcriptase (TERT) promoter hotspot mutations in complex fibroadenomas (CFAs) of the breast. METHODS: The stromal components from 18 CFAs were subjected to Sanger sequencing of MED12 exon 2 and the TERT promoter hotspot loci. The epithelial and stromal components of two MED12 mutated CFAs were subjected to laser capture microdissection, and Sanger sequencing of MED12 exon 2, TERT promoter and PIK3CA exons 9 and 20, separately. RESULTS: MED12 exon 2 mutations were identified in the stroma of 17% of CFAs. The analyses of epithelial and stromal components, microdissected separately, revealed that MED12 mutations were restricted to the stroma. No TERT promoter or PIK3CA mutations in exons 9 and 20 were detected in analysed CFAs. CONCLUSIONS: Like conventional fibroadenomas, MED12 exon 2 mutations appear to be restricted to the stromal component of CFAs, supporting the notion that CFAs are stromal neoplasms.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Fibroadenoma / Complexo Mediador / Mutação Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Fibroadenoma / Complexo Mediador / Mutação Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article